Status:
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
Lead Sponsor:
Pfizer
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people...
Eligibility Criteria
Inclusion
- Participants receiving this Product for treatment of AD.
- Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.
Exclusion
- 1\. Participants previously enrolled in this Study at the same site.
Key Trial Info
Start Date :
April 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 2 2028
Estimated Enrollment :
1128 Patients enrolled
Trial Details
Trial ID
NCT05387980
Start Date
April 19 2022
End Date
August 2 2028
Last Update
December 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Local Country Office
Tokyo, Japan